1. Aebersold P. FDA experience with medical countermeasures under the animal rule. Adv Prev Med. 2012;2012:507–571.
2. US Food and Drug Administration. Guidance for industry: product development under the Animal Rule. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm399217.pdf. Published October 2015. Accessed November 24, 2015.
3. US Food and Drug Administration. Guidance for industry and FDA staff: qualification process for drug development tools. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM230597.pdf. Published January 2014. Accessed November 24, 2015.
4. US Food and Drug Administration. Labeling and review documents for pyridostigmine bromide (NDA 020414). Approved February 5, 2003. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/20414_pyridostigmine.cfm. Published April 16, 2003. Accessed November 24, 2015.
5. US Food and Drug Administration. Labeling and review documents for Cyanokit (NDA 022041). Approved December 15, 2006. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/022041_cyanokit_toc.cfm. Published December 12, 2008. Accessed November 24, 2015.